Xencor (XNCR) Tops Q3 EPS by 37c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BE
8. FIX
9. PNFP
10. NDAQ

Go back to Xencor (XNCR) Tops Q3 EPS by 37c

Xencor Reports Third Quarter 2019 Financial Results

November 5, 2019 4:01 PM EST

-- Management to Host Conference Call at 4:30 p.m. ET today --

MONROVIA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today reported financial results for the third quarter ended September 30, 2019 and provided a review of recent business and clinical highlights.

The plug-and-play nature of Xencors XmAb® technology has enabled the development of a broad and diversified portfolio of therapeutic bispecific antibodies and cytokines, including six programs currently being... More